references
- Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med 2007;356:1915–27.
- Paavonen K, Jenkins D, Bosch X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with HPV types 16 and 18 in young women. Lancet 2007;369:2161–70.
- Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301–14.
- Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 356:1928–43.
- Brown D, Kjaer S, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naïve women aged 16–26 years. J Infect Dis 2009;199:926–35.
- Badia X, Colombo JA, Lara N, et al. Combination of qualitative and quantitative methods for developing a new Health Related Quality of Life measure for patients with anogenital warts. Health Qual Life Outcomes 2005;3:24.
- Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Trans Infect 2008 84:161–6.
- Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: Event duration and health utility loss. Med Dec Making 2007;27:414–22.
- Myers, ER, Green, S, Lipkus, I. Patient preferences for health states related to HPV infection: Visual analogue scales vs time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference, Mexico City, Mexico 2004: Abstract 542.
- Taira A, Neukermans CP, Sander GD. Evaluating human papillomavirus vaccination programs. Emerging Infect Dis 2004;10:1915–23.
- Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604–15.
- Insinga R, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397–403.
- IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 90. Human papillomaviruses. Lyon: World Health Organization International Agency for Research on Cancer; 2007.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
- Aalto A-M, Aro AR, Teperi J. RAND-36 as a measure of Health-Related Quality of Life. In: Stakes Research Reports 101: Reliability, construct validity and reference values in the Finnish general population. Helsinki: Stakes; 1999.
- Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: Results from a United Kingdom national questionnaire survey BMJ 1998;316:736–41.
- Lehtinen M, Idänpään-Heikkilä I, Lunnas T, et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 2006;17:237–46.
- Paavonen J, Future II Study Group. Baseline demographic characteristics of subjects enrolled in quadrivalent HPV (types 6/11/16/18) vaccine clinical trial. Curr Med Res Opin 2008;24:1623–34.